Cambridge Investment Research Advisors Inc. lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 6.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 78,691 shares of the financial services provider’s stock after selling 5,538 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $10,801,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Future Financial Wealth Managment LLC bought a new position in iShares Biotechnology ETF in the 1st quarter valued at about $27,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF during the second quarter valued at approximately $31,000. Pacifica Partners Inc. lifted its stake in iShares Biotechnology ETF by 118.2% during the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Crewe Advisors LLC boosted its holdings in shares of iShares Biotechnology ETF by 42.9% in the 4th quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock valued at $35,000 after purchasing an additional 78 shares in the last quarter. Finally, YHB Investment Advisors Inc. bought a new position in shares of iShares Biotechnology ETF in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
Shares of iShares Biotechnology ETF stock traded down $0.01 during trading on Tuesday, reaching $147.87. 427,093 shares of the company’s stock were exchanged, compared to its average volume of 1,557,285. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $150.17. The firm’s 50-day moving average price is $142.43 and its 200 day moving average price is $137.30.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- How to Invest in Small Cap StocksÂ
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What Are Dividends? Buy the Best Dividend Stocks
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.